Tissue Repair
BPC-157
Body Protection Compound-157; Bepecin; PL 14736
Synthetic pentadecapeptide; cytoprotective
This BPC-157 entry draws on 9 cited sources published 2014 to 2026. The evidence available is graded Anecdotal + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Synthetic pentadecapeptide; cytoprotective
- Drug class
- Tissue Repair
- Structure
- 15-aa peptide GEPPPGKPADDAGLV; MW ~1419 Da; partial sequence of human gastric juice protein
- Route
- SC / IM / Oral / Intranasal
- Half-life
- less than 30 min (IV and IM in rats and dogs; oral not measured)
- Evidence tier
- Anecdotal + Animal Studies
- Availability
- Compounding Restricted
- Research depth
- 190 indexed citations →
Mechanism of action
Promotes angiogenesis via VEGFR2 [1]; upregulates growth factors [1]; modulates NO and dopamine pathways [1]; stabilizes gut barrier [1]
Reported areas of research
Tendon/ligament/muscle healing [2]; gut mucosal repair [1][3]; angiogenesis [1][3]; reduced GI inflammation [1]; wound healing [3]
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1]
Compared with
BPC-157 has published head-to-head comparisons with 7 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for BPC-157 in research literature?
Published peptide research reports the following dosing approach for BPC-157: 250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily. This is a research reference, not a clinical recommendation.
How is BPC-157 administered in research?
BPC-157 is administered via the following routes in published studies: SC / IM / Oral / Intranasal.
What is the reported half-life of BPC-157?
The reported half-life of BPC-157 is less than 30 min (IV and IM in rats and dogs; oral not measured).
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug. BPC-157 was nominated for FDA's bulk drug substance lists, flagged by FDA for possible safety risks, and the nomination was then withdrawn by the party that filed it, which leaves it with no route to lawful compounding rather than with a clean record. On 23 July 2026 FDA's Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895) voted 8 for, 6 against, 1 abstention to recommend BPC-157 for the 503A Bulks List, for ulcerative colitis. The vote is advisory: it adds nothing to the list by itself, and an addition would require a proposed rule, a public comment period and a final rule. PeptideHelper.org catalog status: Compounding Restricted.
Sources: FDA: bulk drug substances that may present significant safety risks; FDA meeting notice and agenda; Fierce Pharma, 23 July 2026; Pharmaceutical Executive, 24 July 2026.
What level of evidence supports BPC-157?
The current evidence base for BPC-157 is best characterised as: Anecdotal + Animal Studies. See the methodology page for the full evidence-tier rubric.
What side effects are reported for BPC-157?
Known concerns reported in the literature for BPC-157 include: Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1]. Always consult a qualified clinician before any human use.
Is there anyone who should not use BPC-157?
No formal contraindications are established for BPC-157, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited human trials; injection site irritation; theoretical pro-angiogenic/tumor concerns. Always consult a qualified clinician before any human use.
How does BPC-157 work?
The mechanism of action reported for BPC-157 in the literature: Promotes angiogenesis via VEGFR2; upregulates growth factors; modulates NO and dopamine pathways; stabilizes gut barrier.
What is BPC-157 studied for?
BPC-157 has been studied in the published literature for: Tendon/ligament/muscle healing; gut mucosal repair; angiogenesis; reduced GI inflammation; wound healing. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is BPC-157?
BPC-157 is classified as: Synthetic pentadecapeptide; cytoprotective. Also known as: Body Protection Compound-157; Bepecin; PL 14736.
Studied in combination
BPC-157 appears in the following peptide combinations discussed in research and practitioner literature:
- GLOW / KLOW, Tissue repair, anti-inflammation, skin regeneration
- Recovery Base, Muscle, tendon, ligament healing
Drug class
- Tissue-repair peptides, see all peptides tagged Tissue-repair.
Research focus area
All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.
Primary sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of pharmacology. Curr Pharm Des 2018. PMID 29804522
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Orthop Res 2014. PMID 24375646
- Seiwerth S et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol 2021. PMID 34267654
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.) 2026. PMID 41966639
- A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery [NCT07752381 NA COMPLETED]
- Luansritisakul C et al. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. Current pain and headache reports 2026. PMID 42635865
- Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery [NCT07803250 PHASE1 NOT_YET_RECRUITING]
- Tham A et al. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. The Journal of the American Academy of Orthopaedic Surgeons 2026. PMID 42937313
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PMID 36588717
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…